Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells

References

• WangAZGuFZhangLBiofunctionalized targeted nanoparticles for therapeutic applicationsExpert Opin Biol Ther2008881063107018613759
   PubMed Web of Science ®Google Scholar
• WangXLiJWangYA folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer modelACS Nano2012586184619421728341
   PubMed Web of Science ®Google Scholar
• LeeRJLowPSFolate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitroBiochim Biophys Acta1995123321341447865538
   PubMed Web of Science ®Google Scholar
• MoffattSPapasakelariouCWiehleSCristianoRSuccessful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591//PEI//DNA molecular conjugateGene Ther200613976177216453011
   PubMed Web of Science ®Google Scholar
• ZhangYFWangJCBianDYZhangXZhangQTargeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studiesEur J Pharm Biopharm201074346747320064608
   PubMed Web of Science ®Google Scholar
• MauriceTSuTPThe pharmacology of sigma-1 receptorsPharmacol Ther2009124219520619619582
   PubMed Web of Science ®Google Scholar
• CobosEJEntrenaJMNietoFRCendanCMDel PozoEPharmacology and therapeutic potential of sigma(1) receptor ligandsCurr Neuropharmacol20086434436619587856
   PubMed Web of Science ®Google Scholar
• JohnCSVilnerBJGeyerBCMoodyTBowenWDTargeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumorsCancer Res199959184578458310493511
   PubMed Web of Science ®Google Scholar
• JohnCSBowenWDSagaTA malignant-melanoma imaging agent – synthesis, characterization, in-vitro binding and biodistribution of Iodine-125-(2-piperidinylaminoethyl)4-IodobenzamideJ Nucl Med19933412216921758254405
   PubMed Web of Science ®Google Scholar
• BanerjeeRTyagiPLiSHuangLAnisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cellsInt J Cancer2004112469370015382053
   PubMed Web of Science ®Google Scholar
• NakagawaOMingXHuangLJulianoRLTargeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligandsJ Am Chem Soc2010132268848884920550198
   PubMed Web of Science ®Google Scholar
• LiSDHuangLTargeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cellsMol Pharm20063557958817009857
   PubMed Web of Science ®Google Scholar
• LiSDChonoSHuangLEfficient oncogene silencing and metastasis inhibition via systemic delivery of siRNAMol Ther200816594294618388916
   PubMed Web of Science ®Google Scholar
• MukherjeeAPrasadTKRaoNMBanerjeeRHaloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cellsJ Biol Chem200528016156191562715695518
   PubMed Web of Science ®Google Scholar
• VilnerBJJohnCSBowenWDSigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor-cell linesCancer Res19955524084137812973
   PubMed Web of Science ®Google Scholar
• WheelerKTWangLMWallenCASigma-2 receptors as a biomarker of proliferation in solid tumoursBr J Cancer20008261223123210735510
   PubMed Web of Science ®Google Scholar
• MatsumotoRRSigma receptors: historical perspective and backgroundMatsumotoRRBowenWDSuTPSigma Receptors: Chemistry, Cell Biology and Clinical ImplicationsNew YorkSpringer2007124
   Google Scholar
• MachRHSmithCRAlNabulsiIWhirrettBRChildersSRWheelerKTSigma-2 receptors as potential biomarkers of proliferation in breast cancerCancer Res19975711561618988058
   PubMed Web of Science ®Google Scholar
• ColabufoNABerardiFContinoMCorrelation between sigma2 receptor protein expression and histopathologic grade in human bladder cancerCancer Lett20062371838816005143
   PubMed Web of Science ®Google Scholar
• KashiwagiHMcDunnJESimonPOSelective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapyMol Cancer200764817631687
   PubMed Web of Science ®Google Scholar
• SpitzerDSimonPOKashiwagiHUse of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signalingCancer Res201172120120922065721
   PubMed Web of Science ®Google Scholar
• Di PaoloDPastorinoFBrignoleCDrug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatmentTumori200894224625318564613
   PubMed Web of Science ®Google Scholar
• VangveravongSXuJZengCMachRHSynthesis of N-substituted 9-azabicyclo[3.3.1] nonan-3α-yl carbamate analogs as σ2 receptor ligandsBioorg Med Chem200614206988699716837201
   PubMed Web of Science ®Google Scholar
• EliazRESzokaFCJrLiposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cellsCancer Res20016162592260111289136
   PubMed Web of Science ®Google Scholar
• MachRHWheelerKTDevelopment of molecular probes for imaging sigma-2 receptors in vitro and in vivoCent Nerv Syst Agents Med Chem20099323024520021357
   PubMedGoogle Scholar
• XuJZengCChuWIdentification of the PGRMC1 protein complex as the putative sigma-2 receptor binding siteNat Commun2011238021730960
   PubMed Web of Science ®Google Scholar
• SpitzerDSimonPOKashiwagiHUse of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signalingCancer Res201272120120922065721
   PubMed Web of Science ®Google Scholar
• LasicDDMartinFJStealth LiposomesBoca RatonCRC Press1995
   Google Scholar
• GabizonAALiposome circulation time and tumor targeting: implications for cancer-chemotherapyAdv Drug Deliv Rev1995162–3285294
   Web of Science ®Google Scholar
• ZhouWYuanXWilsonAEfficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesiclesBioconjug Chem20021361220122512440856
   PubMed Web of Science ®Google Scholar
• WangYXuJXiaXSV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptorsNanoscale20124242142422113350
   PubMed Web of Science ®Google Scholar